MX2020001167A - Metodos y composiciones para el tratamiento de enfermedades por deposicion amiloide. - Google Patents

Metodos y composiciones para el tratamiento de enfermedades por deposicion amiloide.

Info

Publication number
MX2020001167A
MX2020001167A MX2020001167A MX2020001167A MX2020001167A MX 2020001167 A MX2020001167 A MX 2020001167A MX 2020001167 A MX2020001167 A MX 2020001167A MX 2020001167 A MX2020001167 A MX 2020001167A MX 2020001167 A MX2020001167 A MX 2020001167A
Authority
MX
Mexico
Prior art keywords
treatment
methods
amyloid deposition
deposition diseases
amyloid
Prior art date
Application number
MX2020001167A
Other languages
English (en)
Inventor
Suzanne Lentzsch
Original Assignee
Univ Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Columbia filed Critical Univ Columbia
Publication of MX2020001167A publication Critical patent/MX2020001167A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Se divulgan procedimientos y composiciones farmacéuticas para el tratamiento de enfermedades por deposición de amiloide mediante el uso de anticuerpo quimérico (por ejemplo, ratón-humano) que incluyen un método para tratar enfermedades por deposición de amiloide con compromiso cardíaco mediante la administración de composiciones farmacéuticas que comprenden un anticuerpo de fibrilla anti-amiloide quimérico. Los procedimientos en la presente memoria pueden mejorar la función miocárdica en pacientes diagnosticados con amiloidosis de cadena ligera (ALA) que tienen un compromiso cardíaco en tan solo tres semanas después del tratamiento.
MX2020001167A 2017-08-01 2018-07-24 Metodos y composiciones para el tratamiento de enfermedades por deposicion amiloide. MX2020001167A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762539821P 2017-08-01 2017-08-01
US201862637609P 2018-03-02 2018-03-02
PCT/US2018/043374 WO2019027721A2 (en) 2017-08-01 2018-07-24 METHODS AND COMPOSITIONS FOR THE TREATMENT OF AMYLOID DISEASE DISEASES

Publications (1)

Publication Number Publication Date
MX2020001167A true MX2020001167A (es) 2020-11-11

Family

ID=65231894

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020001167A MX2020001167A (es) 2017-08-01 2018-07-24 Metodos y composiciones para el tratamiento de enfermedades por deposicion amiloide.

Country Status (12)

Country Link
US (2) US11382974B2 (es)
EP (1) EP3661553A4 (es)
JP (2) JP2020529990A (es)
KR (3) KR20240046269A (es)
CN (1) CN111867626A (es)
AU (1) AU2018311688B2 (es)
BR (1) BR112020002155A2 (es)
CA (1) CA3071817A1 (es)
IL (1) IL272321A (es)
MX (1) MX2020001167A (es)
RU (1) RU2746812C1 (es)
WO (1) WO2019027721A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3067597C (en) * 2017-06-29 2023-03-21 The Trustees Of Columbia University In The City Of New York Chimeric antibodies for treatment of amyloid deposition diseases
US12018069B2 (en) 2018-06-28 2024-06-25 The Trustees Of Columbia University In The City Of New York Methods and compositions for imaging amyloid deposits
SG11202109645QA (en) 2019-03-05 2021-10-28 Prothena Biosciences Ltd Methods of treating al amyloidosis
MX2022005850A (es) 2019-11-15 2022-08-15 Univ Tennessee Res Found Inmunoglobulinas modificadas para seleccionar depositos de amiloide como objetivo.
AU2021208630A1 (en) * 2020-01-17 2022-07-21 University Of Tennessee Research Foundation Chimeric antigen receptors for removal of amyloid
AU2021339851A1 (en) * 2020-09-14 2023-04-13 Caelum Biosciences, Inc. Method of treating amyloidosis
JP2023548005A (ja) * 2020-10-28 2023-11-15 ノヴォ ノルディスク アー／エス 抗トランスサイレチン抗体およびその使用方法
TW202332465A (zh) * 2021-01-29 2023-08-16 愛爾蘭商普羅希那生物科學有限公司 治療al類澱粉變性症之方法
MX2023013050A (es) * 2021-05-18 2024-01-19 Univ Tennessee Res Found Proteinas de fusion anticuerpo-peptido para el tratamiento de trastornos amiloides.

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
PT1078005E (pt) 1998-05-21 2010-08-30 Univ Tennessee Res Foundation Processo de eleminação de amilóide usando anticorpos antiamilóide
UA81216C2 (en) * 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
SK288711B6 (sk) 2000-02-24 2019-11-05 Univ Washington Humanizovaná protilátka, jej fragment a ich použitie, polynukleová kyselina, expresný vektor, bunka a farmaceutický prostriedok
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
GEP20115195B (en) 2004-07-30 2011-04-11 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and use thereof
RU2429244C2 (ru) 2006-03-23 2011-09-20 Байоарктик Ньюросайенс Аб Улучшенные селективные в отношении протофибрилл антитела и их применение
CN101415729B (zh) 2006-03-30 2013-09-04 葛兰素集团有限公司 针对β-淀粉样蛋白肽的抗体
SG173385A1 (en) 2006-07-14 2011-08-29 Ac Immune S A Ch Humanized antibody against amyloid beta
PL2074145T3 (pl) 2006-10-02 2017-11-30 Ac Immune S.A. Humanizowane przeciwciało przeciw amyloidowi beta
CA2704064A1 (en) 2007-09-13 2009-03-29 University Of Zurich Humanized antibodies against the .beta.-amyloid peptide
US8791243B2 (en) 2007-12-28 2014-07-29 Onclave Therapeutics Limited Treatment and prophylaxis of amyloidosis
US8195594B1 (en) 2008-02-29 2012-06-05 Bryce thomas Methods and systems for generating medical reports
US20090297439A1 (en) 2008-06-02 2009-12-03 Metheresis Translational Research Sa, Anti-met monoclonal antibody, fragments and derivatives thereof for use in tumor diagnosis, corresponding compositions and kits
IN2014CN03555A (es) * 2011-10-25 2015-07-03 Onclave Therapeutics Ltd
FR3012453B1 (fr) 2013-10-31 2015-11-13 Lab Francais Du Fractionnement Proteine chimerique dans le traitement de l’amylose
CA2956820A1 (en) 2014-08-26 2016-03-03 University Of Tennessee Research Foundation Targeting immunotherapy for amyloidosis
KR102602754B1 (ko) 2015-05-20 2023-11-14 얀센 바이오테크 인코포레이티드 경쇄 아밀로이드증 및 다른 cd38-양성 혈액학적 악성종양을 치료하기 위한 항-cd38 항체
WO2017184973A1 (en) 2016-04-22 2017-10-26 University Of Tennessee Research Foundation Identifying amyloidogenic proteins & amyloidogenic risk
CA3067597C (en) 2017-06-29 2023-03-21 The Trustees Of Columbia University In The City Of New York Chimeric antibodies for treatment of amyloid deposition diseases

Also Published As

Publication number Publication date
WO2019027721A3 (en) 2020-03-26
IL272321A (en) 2020-03-31
CA3071817A1 (en) 2019-02-07
US11382974B2 (en) 2022-07-12
KR20230007531A (ko) 2023-01-12
CN111867626A (zh) 2020-10-30
KR20200033309A (ko) 2020-03-27
AU2018311688A1 (en) 2020-02-20
BR112020002155A2 (pt) 2020-07-28
JP2022104998A (ja) 2022-07-12
KR20240046269A (ko) 2024-04-08
US20230114726A1 (en) 2023-04-13
RU2746812C1 (ru) 2021-04-21
JP2020529990A (ja) 2020-10-15
EP3661553A2 (en) 2020-06-10
EP3661553A4 (en) 2021-06-02
WO2019027721A2 (en) 2019-02-07
AU2018311688B2 (en) 2022-02-17
US20190038745A1 (en) 2019-02-07

Similar Documents

Publication Publication Date Title
MX2020001167A (es) Metodos y composiciones para el tratamiento de enfermedades por deposicion amiloide.
PH12021550023A1 (en) Humanized anti-tau antibodies
CO2018005932A2 (es) Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas
CO2018013500A2 (es) Anticuerpos anti-pd-l1 y usos de los mismos
EA202092410A1 (ru) Конъюгаты камптотецина с пептидом
AR099698A1 (es) Anticuerpos contra el c5 que tienen farmacocinética mejorada
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
WO2015157252A8 (en) Treatment of cancer using anti-cd19 chimeric antigen receptor
BR112014018592A2 (pt) composição e método para o diagnóstico e tratamento de doenças associadas à degeneração de neuritos
MX2021009053A (es) Anticuerpo monoclonal recombinante para usarse en el tratamiento de la enfermedad de alzheimer.
AR101740A1 (es) Terapia de combinación y composiciones
BR112016030541A2 (pt) métodos para o tratamento de infecções fúngicas
AR105938A1 (es) Anticuerpo anti-epha4
PH12019501104A1 (en) Novel anti-human muc1 antibody fab fragment
BR112019002730A2 (pt) acetil-leucina, ou um sal farmaceuticamente aceitável da mesma, para uso em um método de tratamento de uma doença neurodegenetativa
CL2019001749A1 (es) Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
MX2019015914A (es) Anticuerpos quiméricos para el tratamiento de enfermedades por deposición de amiloide.
CO2020005919A2 (es) Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas
CL2021002318A1 (es) Métodos de tratamiento de amiloidosis al
CO2019003865A2 (es) Proteína terapéutica
AR115192A1 (es) Anticuerpos
BR112016023011A2 (pt) tratamento de câncer gástrico
EA202191058A1 (ru) Антитела против муцина-16 и способы их применения
EP3840749A4 (en) METHODS OF TREATMENT OF HEART VALVE DISEASES
BR112017002449A2 (pt) tratamento de sintomas associados com terapia de privação androgênica